(firstQuint)The Efficacy of Silymarin as Adjuvant Therapy on Colorectal Cancer Patients Undergoing FOLFIRI Treatment.

 Primary Objective: Use both listed and relatively safe drug, Silymarin, to improve the intestinal side effect of the patients undergoing FOLFIRI chemotherapy.

 Patient Selection and Enrollment: Number of Subjects: Eligible patients will be randomized in 2 arms in the ratio of 1:1, to reach approximately 50 patients in total.

 Plan of the Study: Study Design This is an open-label, randomized, comparative, double arm, single center study to assess efficacy of Silymarin as adjuvant therapy on metastatic colorectal cancer patients undergoing FOLFIRI chemotherapy in Taiwan.

 Subject Number Eligible patients will be randomized in 2 arms in the ratio of 1:1, to reach approximately 50 patients in total.

 Study Schedule Study date: the time getting approval letter issued by both regulatory authority and institutional review board (IRB) Duration of study: From the date of the IRB was approved till the 50th patient was collected.

 Duration of Enrollment: From the date of the IRB was approved till the 50th patient was collected.

 Duration of treatment: From the 1st patient starting chemotherapy till the 50th patient finishing the 6th cycle chemotherapy.

 Duration of follow-up: From the 1st patient starting chemotherapy till 3 months after the 50th patient finishing the 6th cycle chemotherapy.

 The Efficacy of Silymarin as Adjuvant Therapy on Colorectal Cancer Patients Undergoing FOLFIRI Treatment@highlight

Primary objectives: Use both listed and relatively safe drug, Silymarin,s to improve the intestinal side effect of the patients undergoing FOLFIRI chemotherapy.

